Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

Core Insights - Alnylam Pharmaceuticals reported quarterly earnings of $2.9 per share, significantly exceeding the Zacks Consensus Estimate of $1.67 per share, and compared to a loss of $0.5 per share a year ago, representing an earnings surprise of +73.65% [1] - The company achieved revenues of $1.25 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 22.25%, and showing a substantial increase from year-ago revenues of $500.92 million [2] - Alnylam shares have increased approximately 104.7% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes in these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.86 on revenues of $1.18 billion, and for the current fiscal year, it is $4.44 on revenues of $3.56 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Alnylam belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]